11/19
07:06 am
cmmb
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis [Yahoo! Finance]
Low
Report
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis [Yahoo! Finance]
11/19
07:00 am
cmmb
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
Low
Report
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
11/15
11:13 am
cmmb
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $11.00 price target on the stock, down previously from $13.00.
Low
Report
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $11.00 price target on the stock, down previously from $13.00.
11/14
07:09 am
cmmb
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/14
07:00 am
cmmb
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
10/30
07:00 am
cmmb
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
Medium
Report
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
10/15
07:00 am
cmmb
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
High
Report
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
10/2
09:35 am
cmmb
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City
Low
Report
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City
10/1
07:00 am
cmmb
Chemomab Therapeutics to Present at October 2024 Investor Conferences
Medium
Report
Chemomab Therapeutics to Present at October 2024 Investor Conferences
8/28
07:00 am
cmmb
Chemomab Therapeutics to Present at September 2024 Investor Conferences
High
Report
Chemomab Therapeutics to Present at September 2024 Investor Conferences